Peripheral artery disease (PAD) generates tissue ischemia through arterial occlusions and insufficient collateral vessel formation. Vascular insufficiency in PAD occurs despite higher circulating levels of vascular endothelial growth factor A (VEGF-A) 1,2 , a key regulator of angiogenesis. Here we show that clinical PAD is associated with elevated levels of an antiangiogenic VEGF-A splice isoform (VEGF-A 165 b) and a corresponding reduction in levels of the proangiogenic VEGF-A 165 a splice isoform. In mice, VEGF-A 165 b expression was upregulated by conditions associated with impaired limb revascularization, including leptin deficiency, diet-induced obesity, genetic ablation of the secreted frizzled-related protein 5 (Sfrp5) adipokine and transgenic overexpression of Wnt5a in myeloid cells. In a mouse model of PAD, delivery of VEGF-A 165 b inhibited revascularization of ischemic hind limbs, whereas treatment with an isoform-specific neutralizing antibody reversed impaired revascularization caused by metabolic dysfunction or perturbations in the Wnt5a-Sfrp5 regulatory system. These results indicate that inflammationdriven expression of the antiangiogenic VEGF-A isoform can contribute to impaired collateralization in ischemic cardiovascular disease.
Disability attributable to PAD is rising because of an aging population and an increase in the prevalence of metabolic diseases 3 . Lowerextremity ischemia in PAD is painful, disabling, causes nonhealing ulcers and results in 200,000 amputations per year in the United States alone 4, 5 . PAD is thus a major unmet clinical need afflicting approximately 10 million people in the United States 6 . Limb ischemia induced by arterial obstructive lesions is exacerbated by insufficient angiogenesis and collateral vessel formation 7 , processes that are regulated by VEGF-A 8 . Paradoxically, VEGF-A levels are reported to be elevated in patients with advanced PAD 2, 9 . Furthermore, clinical interventions to promote therapeutic angiogenesis by VEGF-A delivery have had limited efficacy in PAD 10, 11 . It is therefore not clear why collateralization and angiogenesis are insufficient in patients with PAD despite raised VEGF-A levels.
Recent work in cancer biology has identified splice variants of human VEGF-A that inhibit angiogenesis [12] [13] [14] [15] . These isoforms arise from differential splicing of exon 8: proximal splice site usage results in an mRNA containing the initial 19 nucleotides of exon 8a, coding for the proangiogenic VEGF-A 165 a protein in humans, whereas distal splice site usage results in expression of exon 8b and the antiangiogenic family of isoforms typified by VEGF-A 165 b (Fig. 1b) . VEGF-A 165 b inhibits canonical VEGF-A signaling by competitive interference with the interaction of proangiogenic isoforms with the VEGF receptor 2 (VEGFR2)-neuropilin 1 (NRP1) receptor complex, thereby preventing full downstream signaling of VEGFR2 (refs. 13,16) . However, the relevance of inhibitory VEGF-A variants to clinical ischemic syndromes, including PAD, remains incompletely defined 17 , and the existence of mouse VEGF-A 165 b has been questioned 18 . More recently, it has been reported that VEGFA mRNA undergoes a translational readthrough event, generating an isoform referred to as VEGF-Ax that contains a 22-amino-acid extension that encompasses exons 8a and 8b and utilizes the exon 8b stop codon 19 . Thus, there is increasing evidence to suggest that regulatory events at the 3′ end of the VEGFA gene are required for precise physiological control of VEGF-A expression.
Consistent with previous reports 2, 9 , we observed higher levels of circulating VEGF-A in patients with PAD compared to controls using an ELISA that does not discriminate between the VEGF-A isoforms ( Fig. 1a and Supplementary Table 1) . To examine the relative presence of the VEGF-A isoform families in patients with PAD, we measured serum levels by immunoblots using antibodies designed to recognize specific epitopes encoded by exons 8a and 8b (Fig. 1b) . We also determined total VEGF-A levels with a pan-VEGF-A antibody, that does not discriminate between isoforms, directed against the N-terminal portion of the molecule. Consistent with in levels of the hVEGFA 165 a transcript and a 4.6-fold increase in levels of the hVEGFA 165 b transcript in the PBMCs of patients with PAD relative to healthy control individuals. Higher PBMC expression of the VEGFA 165 b transcript was strongly associated with higher serum levels of VEGF-A 165 b (r = 0.65, P < 0.0001; data not shown).
Emerging evidence links noncanonical Wnt5a signaling to the control of vascularization in mouse retinas through changes in the splice pattern of VEGFR1, giving rise to soluble fms-like tyrosine kinase-1 (sFlt-1) that functions as a negative regulator of angiogenesis 22, 23 . To evaluate the potential involvement of noncanonical WNT signaling in VEGF-A splicing, we assessed WNT5A levels in PBMCs from healthy controls and patients with PAD. We detected higher levels of WNT5A gene expression in PBMCs from patients with PAD compared to those from controls ( Supplementary Fig. 2a ) but similar levels of sFLT1 (Supplementary Fig. 2b) . To identify the cell population accountable for the increased WNT5A gene expression in PBMCs of patients with PAD, we separated two major cellular fractions, monocytes and non-monocytes, from the PBMC samples for a subset of patients and healthy controls. In both subject groups, WNT5A gene expression was higher in the monocyte compared to the non-monocyte fraction, suggesting that WNT5A is more highly expressed in cells of the monocyte and macrophage lineage (Supplementary Fig. 2c ). In addition, WNT5A transcript levels in circulating monocytes were upregulated in patients with PAD compared with healthy controls, , showing the regions recognized by the N-terminal pan-VEGF-A antibody and the exon 8a-and exon 8b-specific antibodies. Top right, immunoblot analysis of total hVEGF-A, hVEGF-A 165 a and hVEGF-A 165 b protein in serum from patients with PAD (n = 18) and healthy subjects (n = 19). Bottom right, relative levels of pan-hVEGF-A, hVEGF-A 165 a and hVEGF-A 165 b protein, quantified using ImageJ. Protein levels were normalized using the loading control signal. Results are shown as the mean ± s.e.m. (c) Conventional PCR of mRNA extracted from PBMCs of patients with PAD and healthy subjects using primer sets that distinguish between proximal splicing (hVEGFA 165 a, 126 bp) and distal splicing (hVEGFA 165 b, 60 bp) events of exon 8 in human VEGF-A. pcDNA3-VEGFA 165 a and pcDNA3-VEGFA 165 b plasmids were used as positive controls. Sequencing of the 126-bp product (bottom left) and the 60-bp product (bottom right) from five patients with PAD and five healthy control individuals, respectively, revealed that the bands arise from the expected splicing events. M, molecular weight markers. (d) hVEGFA 165 a and hVEGFA 165 b mRNA expression measured by qRT-PCR in PBMCs from patients with PAD (n = 25) and healthy subjects (n = 25). Results are shown as the mean ± s.e.m. All statistical analyses were performed using independent samples Kolmogorov-Smirnov test for independent samples. **P < 0.01, ***P < 0.001.
the ELISA data (Fig. 1a) , we detected higher levels of total human VEGF-A (hVEGF-A) in the serum of patients with PAD (Fig. 1b) . Levels of the proangiogenic hVEGF-A 165 a isoform were reduced in patients with PAD relative to healthy control subjects, whereas levels of the hVEGF-A 165 b isoform were higher in the PAD cohort (Fig. 1b) . Higher expression of the inhibitory VEGF-A 165 b isoform was associated with lower ankle-brachial index, which is used to assess the severity of PAD (Supplementary Fig. 1 ).
Multiple lines of evidence suggest that inflammatory cell activation contributes to the development and clinical expression of PAD 20, 21 . Thus, we determined the transcript levels of hVEGFA 165 a isoforms in peripheral blood mononuclear cells (PBMCs) isolated from either patients with PAD or healthy control individuals. This analysis employed conventional RT-PCR and a primer set that amplifies a region of the common VEGFA 3′ untranslated region (UTR). We were able to identify the two VEGF-A mRNA isoforms using the predicted differences in the lengths of the PCR products corresponding to VEGFA 165 a and VEGFA 165 b stemming from use of the proximal or distal splice sites. The shorter 60-bp fragment, predicted to generate the exon 8b-containing isoform, was preferentially represented in the PBMCs of patients with PAD (Fig. 1c) . In contrast, PBMCs from healthy control patients predominantly produced a 126-bp PCR fragment, consistent with use of the proximal splice site that incorporates the 8a exon. Sequence analysis of the 126-bp and 60-bp PCR products confirmed the predicted exon 7/8a and 7/8b junctions, respectively (Fig. 1c) . We then performed quantitative RT-PCR (qRT-PCR) using different primer sets that specifically amplify either exon 8a-or 8b-containing transcripts (Fig. 1d) . This analysis revealed a 61% decrease npg similar to observations in whole PBMCs samples. Consistent with the concept that WNT5A signaling regulates VEGF-A isoform levels, WNT5A expression in PBMCs was positively associated with serum levels of VEGF-A 165 b (Supplementary Fig. 3a ) and was negatively associated with ankle-brachial index (Supplementary Fig. 3b ).
To investigate whether Wnt5a is functionally relevant to the control of alternative splicing of Vegfa in ischemia-induced regenerative angiogenesis, we employed a mouse model of PAD. In this model, PAD is simulated by unilateral resection of the femoral artery, which leads to a hemodynamic deficit that can be monitored noninvasively by laser Doppler blood flow (LDBF) imaging and anatomically by measuring capillary density. We observed a relatively modest upregulation of Wnt5a in the ischemic limbs of wild-type (WT) C57BL/6J mice at both the protein and mRNA levels ( Supplementary Fig. 4a,b) . Immunohistochemical analyses of the ischemic limbs revealed Wnt5a colocalization with cells positive for the macrophage marker protein Mac2 (also called galectin-3 or Lgals3), indicating that macrophages are a source of Wnt5a in this model (Supplementary Fig. 4c) .
To examine the involvement of Wnt5a in the regulation of Vegfa splicing, we constructed mice overexpressing Wnt5a in myeloid cells by crossing lysozyme M-Cre (LysM-Cre) mice with knock-in mice carrying a Cre-inducible Wnt5a transgene, resulting in LysMWnt5a GOF mice (GOF, gain of function) (Supplementary Fig. 5a ). Compared with WT mice, LysM-Wnt5a GOF mice expressed higher levels of Wnt5a protein and mRNA in hind limbs after ischemic surgery ( Supplementary Fig. 5b,c) , which was associated with increased expression of Mac2 (Supplementary Fig. 5d ), implying an increase in the number of macrophages. Although LysM-Wnt5a GOF mice displayed no detectable baseline phenotype, they had impaired revascularization as determined by LDBF imaging in response to surgical ischemia (Fig. 2a) . Correspondingly, the gastrocnemius muscle of Wnt5a transgenic mice displayed an inability to increase capillary density in response to ischemia, as assessed in histological sections stained with antibody to CD31 (platelet/endothelial cell adhesion molecule 1, also called PECAM1; Fig. 2b ) or isolectin IB4 (data not shown). Consistent with the findings in human PAD, serum levels of total VEGF-A were elevated in LysM-Wnt5a GOF mice at 7 days after surgery, as determined by an ELISA that does not discriminate between isoforms (Fig. 2c) . Using a pan-VEGF-A antibody, western blot analysis of gastrocnemius muscle also revealed an increase in tissue levels of total VEGF-A in response to ischemia, which was further amplified in Wnt5a transgenic mice (Fig. 2d) . Employing an antibody that specifically recognizes the previously reported amino acid sequence encoded by the C-terminal exon, hereafter referred to as mouse exon 8a, we detected an upregulation of VEGF-A 164 a in the ischemic limbs of WT but not LysM-Wnt5a GOF mice. These assays reveal a striking discrepancy between the levels of total VEGF-A and the exon 8a-containing isoform in the ischemic limbs of the transgenic mice. Moreover, despite an increase in total VEGF-A expression in the ischemic limbs of LysM-Wnt5a GOF mice, tyrosine phosphorylation of VEGFR2 was not activated, indicative of impaired VEGF-A signaling under these conditions (Supplementary Fig. 6 ).
Because the structure of the putative mouse VEGF-A 165 b isoform has not been previously described, we constructed PCR primers that span the C-terminal exons and the 3′ UTR region of the Vegfa transcript ( Supplementary Fig. 7 ). Conventional PCR analysis of mRNA isolated from the ischemic gastrocnemius muscle of WT mice revealed a PCR product fragment of 281 bp, the size expected to be generated from the proangiogenic Vegfa 164 a transcript (Fig. 2e) . Sequence analysis of this fragment confirmed the exon 7/8a splice event that is predicted to encode the previously reported six-amino-acid terminal portion of mouse VEGF-A 164 a (Fig. 2f) 24 . In contrast, RT-PCR analysis of limbs from LysM-Wnt5a GOF mice detected a reduction in the levels of the 281-bp fragment and the appearance of a new band at 215 bp (Fig. 2e) . Sequence analysis of this product revealed that this transcript is derived from use of a distal splice junction, whereby exon 7 is joined to a new exon, hereafter referred to as mouse exon 8b (Fig. 2f) . Mouse exon 8b contains a seven-amino-acid open reading frame followed by a stop codon, such that this open reading frame is predicted to contribute to translation of a full-length, mature protein that is 165 amino acids in length and is homologous to human VEGF-A 165 b (Supplementary Fig. 8 ), and is hereafter referred to as mVEGF-A 165 b.
Because mouse VEGF-A 165 b has not been previously characterized, we designed and validated qPCR primers specific for the exon junction 7/8a (mVegfa 164 a primers) or 7/8b (mVegfa 165 b primers) (Supplementary Fig. 9 ). As assessed by qRT-PCR analysis, ischemic surgery led to a 70% increase in levels of the Vegfa 164 a isoform in the hind limbs of WT mice, but levels of this transcript declined by a factor of three in the transgenic mice overexpressing Wnt5a in myeloid cells (Supplementary Fig. 10 ). In contrast, there was a marked elevation in the expression of the Vegfa 165 b isoform in ischemic hind limbs of the transgenic strain. For detection of the protein encoded by the mouse Vegfa 165 b transcript, we produced an antibody to the predicted exon 8b hexapeptide. This antibody did not crossreact with the VEGF-A 164 a protein in immunoblot analyses, and detected the exon 8b-encoded epitope in total VEGF-A immunoprecipitated from ischemic hind limbs of the transgenic mice ( Supplementary Fig. 11 ). Using this antibody, we found that levels of the exon 8b-containing isoform, i.e., VEGF-A 165 b, were upregulated in the ischemic hind limbs of the transgenic mice (Fig. 2g) .
We next performed immunoblot analysis using an antibody that recognizes the VEGFA translational readthrough product that is referred to as VEGF-Ax (Supplementary Fig. 12a ). In contrast to our findings with the antibody that recognizes the exon 8b hexapeptide, which is predicted to be present in both the VEGF-A 165 b and VEGFAx isoforms, we detected no immunoreactive material in the ischemic limbs of WT or transgenic mice using the antibody that recognizes the highly conserved Ax readthrough peptide that is uniquely present in VEGF-Ax (Supplementary Fig. 12b ). Because VEGF-Ax is reported to be widely expressed in human tissues 19 , we reanalyzed a subset of serum samples from patients with PAD or healthy control subjects using antibodies that specifically recognize the unique readthrough portion of VEGF-Ax or the terminal hexapeptide encoded by exon 8b. This analysis detected Ax peptide-immunoreactive material in the sera of both healthy controls and patients with PAD; however, unlike the exon 8b-specific epitope, there was no difference in the levels of the Ax epitope between the two groups ( Supplementary Fig. 12c ).
To explore the functional importance of mVEGF-A 165 b, we constructed an adenoviral vector expressing this isoform (AdmVegfa 165 b) and administered it intravenously to WT mice before hind limb ischemic surgery. Flow recovery in Ad-mVegfa 165 b-treated mice was significantly less than that in control mice by the third day after surgery, and this difference in recovery persisted throughout the time course of the experiment (Fig. 2h) . Quantitative analysis of CD31-positive cells in gastrocnemius muscle on day 14 after surgery revealed that the ischemia-induced increase in capillary density present in control mice was abrogated in Ad-mVegfa 165 b-treated mice (Fig. 2h) , corroborating the LDBF imaging data. To assess the function of endogenous mVEGF-A 165 b, we treated LysM-Wnt5a GOF Fig. 13 ), and then subjected the mice to hind limb ischemic surgery. Mice receiving VEGF-A 165 b-neutralizing antibody displayed improved blood flow reperfusion and increased capillary density in the affected limb compared with LysM-Wnt5a GOF mice receiving an equivalent dose of IgG control antibody (Fig. 2i) . In contrast, WT mice, in which mVEGF-A 165 b expression is not appreciably increased after ischemic surgery, were refractory to treatment with the neutralizing antibody. Collectively, these results show that macrophage expression of Wnt5a inhibits regenerative angiogenesis, at least in part, through upregulation of mVEGF-A 165 b. The secreted protein Sfrp5 is expressed predominantly by adipose tissue, where it inhibits inflammation by suppressing noncanonical Wnt5a signaling in macrophages 25 . We therefore evaluated the effect of Sfrp5 deficiency on ischemia-induced angiogenesis and VEGF-A 165 b expression. As was observed in LysM-Wnt5a GOF mice, Sfrp5 deficiency led to impaired reperfusion and capillary density of ischemic limbs in the PAD model (Supplementary Fig. 14a,b) . To assess the molecular basis for the angiogenic deficiency of the Sfrp5 knockout (KO) mice, we used qRT-PCR to analyze the expression patterns of Wnt family members in the ischemic and non-ischemic gastrocnemius muscle of Sfrp5 KO compared to WT mice. Of the 19 Wnt family members, only the Wnt5a transcript was expressed at a higher level in the ischemic limbs of Sfrp5 KO mice as compared to WT mice (Supplementary Fig. 14c ). Wnt5a protein expression, as assessed by immunoblot analysis, was also markedly upregulated in the ischemic limb muscle of Sfrp5 KO mice ( Supplementary  Fig. 14d ), a result that is attributable to a greater influx of Mac2 and Wnt5a double-positive macrophages (Supplementary Fig. 14e ). Consistent with these findings, immunoblot analysis revealed that Sfrp5 deficiency led to a marked increase in Mac2 expression in the ischemic limb but had no effect on Mac2 expression in the uninjured contralateral limb (Supplementary Fig. 14f) . Thus, Sfrp5 deficiency phenocopies myeloid-specific Wnt5a overexpression in its impairment of regenerative angiogenesis and enhancement of macrophage infiltration in ischemic limbs, and Sfrp5 deficiency can be used as another approach to study the role of the mVEGF-A 165 b isoform.
We next used immunoblot analysis to assess total mouse VEGF-A, VEGF-A 164 a and VEGF-A 165 b expression in hind limb muscle from Sfrp5 KO and WT mice. As was observed in LysM-Wnt5a GOF mice, Sfrp5 KO mice showed an increase in total VEGF-A protein Fig. 14g,h) . Assessment of isoform-specific qPCR of transcripts in the ischemic and non-ischemic gastrocnemius muscle revealed a modest upregulation of the exon 8a-containing mVegfa 164 a isoform in WT mice after surgery. However, the exon 8b-containing mVegfa 165 b isoform was selectively upregulated in the ischemic muscle of Sfrp5 KO mice (Supplementary Fig. 14i ).
To assess the functional importance of mVEGF-A 165 b upregulation, we administered the VEGF-A 165 b-neutralizing antibody or control IgG to Sfrp5 KO mice before hind limb surgery. Ischemic limbs of Sfrp5 KO mice receiving the neutralizing antibody had increased reperfusion, as determined by LDBF ( Supplementary  Fig. 14j ) and an increase in capillary density in the gastrocnemius muscle of the ischemic limb relative to the contralateral control limb; in contrast, Sfrp5 KO mice treated with IgG showed no increase in capillary density (Supplementary Fig. 14j ). Collectively, these data indicate that the antiangiogenic mVEGF-A 165 b splice variant is upregulated in response to ischemia in both Sfrp5 KO and LysMWnt5a GOF mice and that this upregulation contributes to an impaired angiogenic response. PAD is strongly associated with diabetes mellitus 26 , and studies in experimental models have shown that metabolic dysfunction leads to a reduction in the angiogenic response to tissue ischemia 27 . Because perturbations in the Sfrp5-Wnt5a regulatory system contribute to systemic metabolic dysfunction under conditions of obesity 25 , we evaluated the regulation and function of the antiangiogenic mVEGF-A 165 b isoform in models of diet-induced obesity and leptin deficiency. Consistent with observations in adipose tissue 25 , Wnt5a protein and mRNA expression were elevated in the ischemic muscle of mice fed a high fat and high sucrose (HF/HS) diet or ob/ob mice relative to mice fed a standard chow diet or C57BL/6J mice, respectively (Fig. 3a,b and Supplementary Fig. 15a,b) . The increase in Wnt5a expression in muscle tissue under conditions of metabolic dysfunction was associated with an increase in the infiltration of Wnt5a and Mac2 double-positive macrophages ( Fig. 3c and  Supplementary Fig. 15c ). Western blot analysis of gastrocnemius muscle from these experimental groups of mice revealed upregulation of VEGF-A expression in both the HF/HS-fed and ob/ob mice using a pan-VEGF-A antibody that does not discriminate between the isoforms (Fig. 3d and Supplementary Fig. 15d ). Isoform-specific antibodies revealed modest upregulation of the mVEGF-A 164 a isoform in ischemic limbs of metabolically normal mice; in contrast, the HF/HS-fed and ob/ob mice displayed marked elevations in the levels of the antiangiogenic mVEGF-A 165 b isoform ( Fig. 3d and  Supplementary Fig. 15d ). Using antibodies specific for the unique npg VEGF-Ax extension peptide or the exon 8b-encoded hexapeptide, we detected exon 8b-containing but no Ax extension peptide-containing material in ob/ob mice (Supplementary Fig. 15e ) or HF/HS-fed mice (data not shown) under the conditions of our assays. Corroborating the findings with the isoform-specific antibodies, isoform-specific qPCR of Vegfa cDNA isolated from gastrocnemius muscle revealed that metabolic dysfunction led to reduced expression of the proangiogenic Vegfa isoform and increased expression of the antiangiogenic exon 8b-containing isoform (Fig. 3e and Supplementary Fig. 15f) . HF/HS-fed and ob/ob mice both displayed impaired revascularization as assessed by LDBF imaging and capillary and arteriole density analyses (Fig. 3f and Supplementary Figs. 15g and 16) . To assess the functional importance of mVEGF-A 165 b under these conditions of metabolic dysfunction, we treated both ob/ob and HF/HS-fed C57BL/6 mice with VEGF-A 165 b-neutralizing antibody or IgG control and subjected them to hind limb ischemic surgery. Whereas the neutralizing antibody had no effect on the angiogenic response in metabolically normal mice, antibody treatment of both the ob/ob and HF/HS-fed mice led to significant improvements in ischemic limb revascularization ( Fig. 3f and Supplementary Figs. 15g and 16) .
To examine how VEGF-A 165 b expression is regulated at a mechanistic level, we treated cultured RAW264.7 cells, a mouse macrophage line, with recombinant Wnt5a. Wnt5a stimulation led to a dose-dependent increase in VEGF-A 165 b levels (Fig. 4a) , as well as upregulation of the Vegfa 165 b splice variant at the mRNA level (Fig. 4b) . Consistent with previous work showing that Wnt5a signals in a noncanonical manner 28 , knockdown of Ror2, a Frizzled co-receptor protein, abolished Wnt5a-mediated Vegfa 165 b induction (Fig. 4b) . Also consistent with a noncanonical signaling mechanism, Wnt5a treatment led to the activation of JNK (Fig. 4c) , and pretreatment with the JNK inhibitor SP600125 abolished Wnt5a-mediated Vegfa 165 b expression (Fig. 4d) . Similarly, treatment with recombinant Sfrp5 protein blocked VEGF-A 165 b expression under these conditions (Fig. 4d) . Further investigation revealed that Wnt5a upregulated the expression of SC35, a pre-mRNA splicing factor implicated in the alternative processing of Vegfa at exon 8 (ref. 29) , in a JNK-and Sfrp5-dependent manner (Fig. 4e) . Knockdown of SC35 blocked Wnt5a-mediated induction of Vegfa 165 b (Fig. 4f) . Collectively, these data indicate that Wnt5a promotes the processing of Vegfa to yield the exon 8b-containing isoform, at least in part, through an Ror2-JNK-SC35-dependent mechanism (Fig. 4g) .
Here we show that the antiangiogenic splice variant of VEGF-A is expressed in clinical and experimental settings that are associated with impaired vascularization. It has been noted previously, and confirmed here, that total VEGF-A levels are paradoxically elevated in patients with PAD 2,9 . Using isoform-specific antibodies, we provide evidence that circulating VEGF-A in patients with PAD is comprised predominantly of the variant VEGF-A 165 b isoform. In mouse experimental models, we established the presence of mVEGF-A 165 b and demonstrated upregulation of its expression under conditions of systemic metabolic dysfunction. In contrast, we did not detect the VEGF-Ax isoform under these conditions. Although VEGF-Ax was present in human serum, we did not observe its upregulation in a small cohort of patients with PAD. However, VEGF-Ax levels should be further evaluated using a larger number of patients, as well as different metabolic phenotypes. We also demonstrated that the VEGF-A 165 b isoform impairs revascularization in an experimental model of PAD. Conversely, acute immunological neutralization of mVEGF-A 165 b promotes revascularization of ischemic tissue under conditions in which the process of regenerative angiogenesis is impaired. These findings support the concept that VEGF-A 165 b may serve as a new pharmacological target to treat limb ischemia in patients with PAD and that its neutralization may augment the activities of proangiogenic growth factors.
Metabolic diseases, including diabetes and obesity, contribute to ischemic cardiovascular disease, but the molecular mechanisms underlying this pathological connection remain incompletely defined. Obesity-linked changes in the expression of adipose tissue-derived Sfrp5 can lead to overactivation of noncanonical Wnt5a signaling in macrophages that, in turn, promotes inflammation and systemic metabolic dysfunction, but the link between this signaling and vascular disease had not previously been identified 25 . We now show that Sfrp5 deficiency impairs the hind limb revascularization response to ischemia. This impairment is associated with greater infiltration of activated, Wnt5a-positive macrophages in the ischemic tissue. Myeloid-specific Wnt5a overexpression parallels Sfrp5 deficiency, with exaggerated macrophage infiltration and blunted revascularization in ischemic limbs. In both models, we demonstrated upregulation of the mVEGF-A 165 b isoform in ischemic tissue and showed that immunological neutralization of this inhibitory VEGF-A isoform promotes the angiogenic response to ischemia. These data indicate that Wnt5a, and its upstream effector Sfrp5, mediate the effects of metabolic dysfunction on regenerative angiogenesis by controlling macrophage expression of VEGF-A 165 b. Taken together, our findings identify the Sfrp5-Wnt5a-VEGF-A 165 b axis as a regulator of the vascular response to ischemia in the setting of metabolic disease and provide a new potential mechanism for the link between obesity and cardiovascular disease.
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oNLINE METHoDS
Clinical samples. Patients with PAD (defined as ankle-brachial index <0.9 or prior revascularization) and control individuals without PAD (ankle-brachial index >1.0 and <1.4) were enrolled from outpatient clinics at Boston Medical Center. The Boston Medical Center Institutional Review Board approved the study, and all participants provided written informed consent. Ankle-brachial index was measured using a Doppler probe to record systolic pressure in the brachial, posterior tibial and dorsalis pedis arteries and by obtaining the ratio of ankle to arm pressure. The lowest leg ankle-brachial index is reported 30 . On the day of the visit, fasting blood samples were obtained to measure lipids and glucose. PBMCs were isolated by density gradient centrifugation in Vacutainer cell preparation tubes (CPT tubes with sodium citrate, Becton-Dickinson), treated with an RNA stabilizer (RNAlater, Qiagen) and stored at −80 °C before RNA isolation.
ELISA. Total circulating levels of VEGF-A from patients with PAD and healthy subjects and in mouse serum after hind limb ischemia were measured with quantitative colorimetric sandwich ELISAs (R&D Systems, human: DVE00, mouse: MMV00). Circulating levels of mouse sFlt-1 in WT, LysM-Wnt5a GOF and Sfrp5 KO mice were measured with a quantitative colorimetric sandwich ELISA (R&D Systems, MVR100). For all ELISAs, protein concentrations were calculated using a standard curve generated with recombinant standards provided by the manufacturer. Optical density was measured using a microtiter plate reader at 450 nm. Each sample was measured in duplicate and averaged.
Human monocyte isolation. The Human Monocyte Isolation Kit II (Miltenyi Biotech) was used to magnetically separate monocytes from non-monocytes following the manufacturer's recommendations. Non-monocyte cells in PBMC samples were magnetically labeled using a cocktail of antibodies against the non-monocyte antigens CD3, CD7, CD16, CD19, CD56, CD123 and glycophorin A. Monocyte (unlabeled) and non-monocyte (labeled) fractions were then separated with Miltenyi MS columns and a MiniMacs separator.
Mice. Mice with myeloid-restricted Wnt5a overexpression were generated by crossing lysozyme M-Cre (LysM-Cre) mice (Jackson Laboratories, stock number 004781) with knock-in mice carrying a Cre-inducible Wnt5a transgene (Supplementary Fig. 5a ). Mice (C57BL/6, Charles River Laboratory) were fed either a standard chow diet (Harlan Teklad global 18% protein rodent diet, #2018) or a HF/HS diet (Bio-Serv, #F1850) 25 , as indicated. The composition of the HF/HS diet was 35.8% fat (primarily lard), 36.8% carbohydrate (primarily sucrose) and 20.3% protein. For the feeding of the high-caloric diet, 4-week-old mice were maintained on a HF/HS diet for 8 weeks. Mice lacking Sfrp5 were described previously 25 . Sfrp5 KO mice and C57BL/6J WT mice were used in this study. ob/ob (stock number 000632), 8-week-old male mice were purchased from Jackson Laboratory. Study protocols were approved by the Boston University Institutional Animal Care and Use Committee.
Reagents. Recombinant human VEGF-A 165 (293-VE-010), human VEGF-A 165 b (3045-VE-025), mouse VEGF-A 164 (493-MV-025), human (6266-SF-050) and mouse Sfrp5 (7195-SF-050) and human/mouse Wnt5a (645-WN-010) were purchased from R&D systems. Polyhistidine-tagged VEGF-Ax Ala was prepared from HEK292-6E cells as described previously 19 . α-tubulin antibody (11H10, 1:1,000) was purchased from Cell Signaling Technology. Wnt5a antibody (MAB645, 1:250) was purchased from R&D Systems. Lamin A/C (#2032, 1:1,000), JNK (#9252, 1:500), pJNK (Thr183/Tyr185, #9912, 1:500), VEGFR2 and pVEGFR2 (Tyr951, 1:500) antibodies were purchased from Cell Signaling Technology. SC35 antibody (#556363, 1:500) was purchased from BD Pharmingen. VEGF-A (A-20, sc-152, 1:1,000), phosphotyrosine (PY99, 1:200), Flk-1 (VEGFR2; A-3, 1:1,000) and galectin-3 (H-160, 1:1,000) antibodies were purchased from Santa Cruz Biotechnology. The immunogen for the VEGF-A antibody, sc-152, maps within amino acids 1-50 at the N terminus of human VEGF-A (protein accession P15692). The A-20 antibody cross reacts with all human and mouse VEGF-A isoforms. A neutralizing monoclonal antibody against human VEGF-A 165 b was generated by immunizing 6-to 8-week-old female BALB/c mice with a synthetic peptide fragment corresponding to the nine-amino-acid C-terminal sequence of VEGF-A 165 b (TCRSLTRKD) coupled to keyhole limpet hemocyanin (KLH). Specificity was determined by immunoblot analysis using recombinant VEGF-A 165 b and VEGF-A 165 a (data not shown). A C-terminal (exon 8b)-specific antibody was purchased from Abcam. A polyclonal antibody specific to the C terminus (exon 8a) of human VEGF-A 165 a was generated by immunization of a rabbit with a KLH-conjugated peptide, TCRCDKPRR, corresponding to the last nine amino acids of VEGF-A 165 a, using standard immunization techniques. IgG was affinity purified from plasma and its selectivity determined by immunoblotting (data not shown). A polyclonal antibody specific to the C terminus (exon 8b) of mouse VEGF-A 165 b was generated by immunizing rabbits with a combination of two synthetic peptides (CRPLTGKTD-OH conjugated to KLH and unconjugated acetyl-QSKNILMQYIKANSFIGITELCRPLTGKTD-OH) (21st Century Biochemicals). A polyclonal antibody against VEGF-Ax was generated by immunizing a rabbit with the synthetic KLH-conjugated peptide, AGLEEGASLRVSGTR, that is not present in the VEGF-A 165 b isoform 19 .
Conventional PCR and qRT-PCR. mRNA was extracted from human mononuclear cells and gastrocnemius muscle tissue of mice using an RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. cDNA was produced using 1 µg of starting mRNA and the QuantiTect Reverse Transcription Kit (Qiagen) as directed by the manufacturer. Conventional PCR was performed to differentiate between exon 8a-and 8b-containing isoforms. Taking advantage of the fact that the exon 8b-containing isoform is 66-bp shorter than the exon 8a-containing isoform, human and mouse primers were designed to amplify the region spanning the proximal and distal splice sites in human VEGFA 165 a and VEGFA 165 b and in mouse Vegfa 164 a and Vegfa 165 b (Supplementary Fig. 7 ). Conventional PCR analysis was performed using the following conditions: 96 °C for 2 min followed by 45 cycles at 96 °C for 30 s, 60 °C for 30 s and 72 °C for 30 s. The primers used were 5′-AAGGCGAGGCAGCTTGAGTTA-3′ and 5′-TCAGTCTTTCCTGGTGAGAG-3′ for human VEGFA 165 a and VEGFA 165 b and 5′-CAGAAAATCACTGTGAGCCTTGTT-3′ and 5′-ATT AAGGACTGTTCTGTCAA-3′ for mouse Vegfa 164 a and Vegfa 165 b. Exonspecific qRT-PCR was performed with the Applied Biosystems VIIA7 real-time PCR detection system using SYBR Green I as a double-strand DNA-specific dye according to the manufacturer's instructions (Applied Biosystems). Primers were designed to recognize the exon 5/7 junction and the 7/8a or 7/8b junction. mRNA levels were expressed relative to the levels of GAPDH. Realtime RT-PCR analysis was performed using the following conditions: 95 °C for 10 min followed by 45 cycles at 95 °C for 15 s, 64 °C for 30 s and 72 °C for 30 s. Other primer sequences used are described in Supplementary Table 2. Immunoblot analysis. Clinical serum samples were resolved by SDS-PAGE. Mouse gastrocnemius muscle tissue samples obtained on day 3 or 7 after surgery were homogenized in lysis buffer containing 20 mM Tris-HCl (pH 8.0), 1% Nonidet P-40, 150 mM NaCl, 0.5% deoxycholic acid, 1 mM sodium orthovanadate and a protease and phosphatase inhibitor cocktail (Thermo Scientific). Protein content was determined by the Bradford method. Equal amounts of protein lysates were resolved by SDS-PAGE. The membranes were immunoblotted with the indicated antibodies at a 1:1,000 dilution followed by the secondary antibody conjugated to horseradish peroxidase at a 1:1,000-5,000 dilution. An ECL western blotting detection kit (Thermo Scientific) was used for detection. Protein levels quantitated from immunoblots were normalized using loading controls.
Immunoprecipitation. Immunoprecipitation was performed using magnetic beads coated with sheep anti-rabbit IgGs (Dynabeads M-280, Dynal) or protein G from the Dynabeads immunoprecipitation kit (10007D, Life Technologies). Beads were incubated overnight at 4 °C with rabbit anti-mouse VEGF-A 165 b antibody (1 µg antibody for 4 × 10 7 beads) in PBS and 1% skim milk, followed by overnight incubation at 4 °C with 100 µg protein in the presence of a protease and phosphatase inhibitor cocktail (Thermo Scientific). Bound proteins were eluted from the beads by boiling in 25 µl of SDS-PAGE sample buffer.
PAD model of revascularization. WT, LysM-Wnt5a GOF and Sfrp5 KO mice (both in a C57BL/6J background), HF/HS-fed (C57BL/6 background) and npg
